Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 591 - 600 of 692 studies

Oral and Gastrointestinal

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23)

Renal and Urogenital

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of RO7434656, An Antisense Inhibitor Of Complement Factor B, In Patients With Primary IgA Nephropathy At High Risk Of Progression (IMAGINATION)

A Phase 2a, Multi Centre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of 12 Weeks Treatment with Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants with Isolated Rapid Eye Movement Sleep Behavior Disorder (iRDB)

A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

Oral and Gastrointestinal

A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease (MACARONI-23)

Neurological

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (XPF-010-303)

Cardiovascular

HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation (HERMES)

Metabolic and Endocrine

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia

Cancer and neoplasms

A Phase Iii, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib In Combination With Phesgo Versus Placebo In Combination With Phesgo After First Line Induction Therapy In Participants With Pik3ca‑Mutated Her2-Positive Locally Advanced Or Metastatic Breast Cancer (INAVO122)

NIHR BioResource for Translational Research - linked to NIHR203975 PID 16514